Literature DB >> 34798166

Methylation of the serotonin transporter gene moderates the depressive subjective effect of cocaine.

Riley B Longtain1, David P Graham2, Mark J Harding1, Richard De La Garza Ii3, David A Nielsen1.   

Abstract

Genetic variation in the serotonin transporter (SLC6A4) has been shown to moderate the acute subjective effects of cocaine. Methylation of the SLC6A4 gene is associated with decreased transcription of the serotonin transporter, leading to increased serotonin in the synapse. In this study, methylation of the SLC6A4 gene was investigated in the moderation of the subjective effects of cocaine. Non-treatment-seeking cocaine-dependent individuals (N = 53) were intravenously administered cocaine (40 mg) and saline in a randomized order. The subjective effects of cocaine were self-reported using a visual analog scale starting prior to the administration of cocaine (-15 min) or saline and up to 20 min after infusion. Participants were evaluated for methylation of the SLC6A4 promoter region and 5-HTTLPR genotype. A series of ANCOVAs for SLC6A4 methylation (high/low) were run for each of ten subjective and three cardiovascular effects controlling for age, sex [utilizing the sex-determining region Y protein (SRY)], and population structure (determined from ancestry informative markers and STRUCTURE software). Participants with SLC6A4 hypermethylation reported greater subjective response to cocaine for 'depressed' relative to participants with SLC6A4 hypomethylation (experiment-wise p = 0.002). These findings indicate that SLC6A4 methylation moderates the 'depressed' subjective effect of cocaine in non-treatment-seeking cocaine-dependent participants. Published by Elsevier B.V.

Entities:  

Keywords:  Cocaine; Epigenetics; Methylation; Serotonin

Mesh:

Substances:

Year:  2021        PMID: 34798166      PMCID: PMC8671356          DOI: 10.1016/j.bbr.2021.113675

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  47 in total

1.  Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins.

Authors:  Kenneth S Kendler; Kristen C Jacobson; Carol A Prescott; Michael C Neale
Journal:  Am J Psychiatry       Date:  2003-04       Impact factor: 18.112

2.  Promoter Activity-Based Case-Control Association Study on SLC6A4 Highlighting Hypermethylation and Altered Amygdala Volume in Male Patients With Schizophrenia.

Authors:  Tempei Ikegame; Miki Bundo; Naohiro Okada; Yui Murata; Shinsuke Koike; Hiroko Sugawara; Takeo Saito; Masashi Ikeda; Keiho Owada; Masaki Fukunaga; Fumio Yamashita; Daisuke Koshiyama; Tatsunobu Natsubori; Norichika Iwashiro; Tatsuro Asai; Akane Yoshikawa; Fumichika Nishimura; Yoshiya Kawamura; Jun Ishigooka; Chihiro Kakiuchi; Tsukasa Sasaki; Osamu Abe; Ryota Hashimoto; Nakao Iwata; Hidenori Yamasue; Tadafumi Kato; Kiyoto Kasai; Kazuya Iwamoto
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

3.  Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder.

Authors:  Xian-Zhang Hu; Robert H Lipsky; Guanshan Zhu; Longina A Akhtar; Julie Taubman; Benjamin D Greenberg; Ke Xu; Paul D Arnold; Margaret A Richter; James L Kennedy; Dennis L Murphy; David Goldman
Journal:  Am J Hum Genet       Date:  2006-03-28       Impact factor: 11.025

4.  Cocaine modulation of central monoaminergic neurotransmission.

Authors:  D K Pitts; J Marwah
Journal:  Pharmacol Biochem Behav       Date:  1987-02       Impact factor: 3.533

5.  Serotonin transporter mRNA levels are associated with the methylation of an upstream CpG island.

Authors:  Robert Philibert; Anup Madan; Allan Andersen; Remi Cadoret; Hans Packer; Harinder Sandhu
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2007-01-05       Impact factor: 3.568

Review 6.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

Authors:  D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

Review 7.  The neurobiology of individual differences in complex behavioral traits.

Authors:  Ahmad R Hariri
Journal:  Annu Rev Neurosci       Date:  2009       Impact factor: 12.449

8.  Combining genetic and epigenetic parameters of the serotonin transporter gene in obsessive-compulsive disorder.

Authors:  Edna Grünblatt; Zoya Marinova; Alexander Roth; Elena Gardini; Juliane Ball; Julia Geissler; Tomasz K Wojdacz; Marcel Romanos; Susanne Walitza
Journal:  J Psychiatr Res       Date:  2017-10-16       Impact factor: 4.791

9.  Association study of polymorphism in the serotonin transporter gene promoter, methylation profiles, and expression in patients with major depressive disorder.

Authors:  Jun-Ichi Iga; Shin-Ya Watanabe; Shusuke Numata; Hidehiro Umehara; Akira Nishi; Makoto Kinoshita; Masatoshi Inoshita; Shinji Shimodera; Hirokazu Fujita; Tetsuro Ohmori
Journal:  Hum Psychopharmacol       Date:  2016-03-23       Impact factor: 1.672

10.  Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs.

Authors:  Dawn D Han; Howard H Gu
Journal:  BMC Pharmacol       Date:  2006-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.